Climb Bio

CLYM Rare disease Lead: Phase 2 7 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-05

Catalyst timeline

Budoprutug Ph1 interim2H 2026Budoprutug Ph1 interim, 2H 2026, material
Budoprutug SC formulation Ph1 readout4Q 2026Budoprutug SC formulation Ph1 readout, 4Q 2026, material
Budoprutug Ph2 toplineOct 24, 2026Budoprutug Ph2 topline, Oct 24, 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

budoprutug

Protein Target: CD19

Primary Membranous Nephropathy Phase 2 intravenous
Immune Thrombocytopenia Phase 1 Phase 1b/2a trial intravenous NCT07043946
Systemic Lupus Erythematosus Phase 1 intravenous
Systemic Lupus Erythematosus Phase 1 subcutaneous
Primary Membranous Nephropathy Phase 1 subcutaneous

CLYM116

MIL116

Protein Target: APRIL

IgA Nephropathy Phase 2 Mabworks Biotech NCT07248865

ETX-123

Small Molecule Target: Kv7.2/3

Undisclosed indication

Biotech Distilled coverage (7)

2026-09-03 UPDATE: Climb Bio (CLYM) - The Sweeper Delivers Its Number 🔒 Paid
2026-08-07 UPDATE: Climb Bio (CLYM) - The Sweeper Gets a Date 🔒 Paid
2026-06-11 UPDATE: Climb Bio (CLYM) - The ITP Bar Clears
2026-06-05 UPDATE: Climb Bio (CLYM) - The Sweeper Clears Its First Bar
2026-05-06 UPDATE: Climb Bio (CLYM) - The SC Wedge Lands 🔒 Paid
2026-04-29 UPDATE: Climb Bio (CLYM) - The Smart Money Doubles Down 🔒 Paid
2026-04-23 Climb Bio (CLYM) - Scientific Deep Dive for Budoprutug and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.